Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease

Stem Cell Reports

Volumn 8, Issue 4, 2017, Pages 870-882

  Brownjohn, Philip W ^a   Smith, James ^a   Portelius, Erik ^b,c   Serneels, Lutgarde ^d,e   Kvartsberg, Hlin ^b,c   De Strooper, Bart ^d,e,f   Blennow, Kaj ^b,c   Zetterberg, Henrik ^b,c,f   Livesey, Frederick J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid beta; dementia; Down syndrome; human neurons; iPSCs; ivermectin; neural stem cells; phenotypic screening; selamectin

Indexed keywords

ABAMECTIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AVERMECTIN DERIVATIVE; E 2012; EMAMECTIN BENZOATE; FLURBIPROFEN; GAMMA SECRETASE; IVERMECTIN; MILBEMYCIN; MOXIDECTIN; SELAMECTIN; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT; AVERMECTIN; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DOWN SYNDROME; DRUG DESIGN; DRUG SCREENING; FEASIBILITY STUDY; GENETIC MODEL; HUMAN; HUMAN CELL; NEURAL STEM CELL; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING; ANALOGS AND DERIVATIVES; CELL CULTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHENOTYPE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTHELMINTICS; CELLS, CULTURED; DOWN SYNDROME; DRUG DISCOVERY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; IVERMECTIN; NEUROGENESIS; NEURONS; PHENOTYPE;

EID: 85014627907     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2017.02.006     Document Type: Article

References (50)

1. Boutros, M., Bras, L.P., Huber, W., Analysis of cell-based RNAi screens. Genome Biol., 7, 2006, R66.
2. Brideau, C., Gunter, B., Pikounis, B., Liaw, A., Improved statistical methods for hit selection in high-throughput screening. J. Biomol. Screen. 8 (2003), 634–647.
3. Burkhardt, M.F., Martinez, F.J., Wright, S., Ramos, C., Volfson, D., Mason, M., Garnes, J., Dang, V., Lievers, J., Shoukat-Mumtaz, U., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell Neurosci. 56 (2013), 355–364.
4. Chavez-Gutierrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31 (2012), 2261–2274.
5. Dawson, G.R., Wafford, K.A., Smith, A., Marshall, G.R., Bayley, P.J., Schaeffer, J.M., Meinke, P.T., McKernan, R.M., Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. 295 (2000), 1051–1060.
6. Ebert, A.D., Yu, J., Rose, F.F. Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A., Svendsen, C.N., Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457 (2009), 277–280.
7. Ertekin-Taner, N., Genetics of Alzheimer's disease: a centennial review. Neurol. Clin. 25 (2007), 611–667 v.
8. Findeis, M.A., The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol. Ther. 116 (2007), 266–286.
9. Fisher, M.H., Mrozik, H., The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 32 (1992), 537–553.
10. Hall, A., Patel, T.R., γ-Secretase modulators: current status and future directions. Prog. Med. Chem. 53 (2014), 101–145.
11. Hardy, J., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12 (1991), 383–388.
12. Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992), 184–185.
13. Inglese, J., Johnson, R.L., Simeonov, A., Xia, M., Zheng, W., Austin, C.P., Auld, D.S., High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3 (2007), 466–479.
14. Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482 (2012), 216–220.
15. Khurana, V., Tardiff, D.F., Chung, C.Y., Lindquist, S., Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat. Rev. Neurol. 11 (2015), 339–350.
16. Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers-Nolten, I., Van Der Werf, K., Subramaniam, V., et al. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 29 (2010), 3408–3420.
17. Lee, G., Ramirez, C.N., Kim, H., Zeltner, N., Liu, B., Radu, C., Bhinder, B., Kim, Y.J., Choi, I.Y., Mukherjee-Clavin, B., et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat. Biotechnol. 30 (2012), 1244–1248.
18. Mattson, M.P., Magnus, T., Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7 (2006), 278–294.
19. Mecozzi, V.J., Berman, D.E., Simoes, S., Vetanovetz, C., Awal, M.R., Patel, V.M., Schneider, R.T., Petsko, G.A., Ringe, D., Small, S.A., Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10 (2014), 443–449.
20. Moore, S., Evans, L.D., Andersson, T., Portelius, E., Smith, J., Dias, T.B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 11 (2015), 689–696.
21. Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., Cowan, C., Hochedlinger, K., Daley, G.Q., Disease-specific induced pluripotent stem cells. Cell 134 (2008), 877–886.
22. Portelius, E., Tran, A.J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., Westman-Brinkmalm, A., Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 6 (2007), 4433–4439.
23. Portelius, E., Dean, R.A., Gustavsson, M.K., Andreasson, U., Zetterberg, H., Siemers, E., Blennow, K., A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res. Ther., 2, 2010, 7.
24. Portelius, E., Van Broeck, B., Andreasson, U., Gustavsson, M.K., Mercken, M., Zetterberg, H., Borghys, H., Blennow, K., Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J. Alzheimers Dis. 21 (2010), 1005–1012.
25. Portelius, E., Zetterberg, H., Dean, R.A., Marcil, A., Bourgeois, P., Nutu, M., Andreasson, U., Siemers, E., Mawuenyega, K.G., Sigurdson, W.C., et al. Amyloid-beta(1-15/16) as a marker for gamma-secretase inhibition in Alzheimer's disease. J. Alzheimers Dis. 31 (2012), 335–341.
26. Portelius, E., Appelkvist, P., Stromberg, K., Hoglund, K., Characterization of the effect of a novel gamma-secretase modulator on Abeta: a clinically translatable model. Curr. Pharm. Des. 20 (2014), 2484–2490.
27. Prichard, R., Menez, C., Lespine, A., Moxidectin and the avermectins: consanguinity but not identity. Int. J. Parasitol. Drugs Drug Resist. 2 (2012), 134–153.
28. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006), 24–26.
29. Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., Masters, C.L., Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 320 (1989), 1446–1452.
30. Sanchez-Danes, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jimenez-Delgado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 4 (2012), 380–395.
31. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994), 491–502.
32. Shan, Q., Haddrill, J.L., Lynch, J.W., Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J. Biol. Chem. 276 (2001), 12556–12564.
33. Shi, Y., Kirwan, P., Livesey, F.J., Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 7 (2012), 1836–1846.
34. Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S.H., Livesey, F.J., A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med., 4, 2012, 124ra129.
35. Shi, Y., Kirwan, P., Smith, J., Robinson, H.P., Livesey, F.J., Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 15 (2012), 477–486 S471.
36. Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del-Favero, J., Cruts, M., van Duijn, C.M., Van Broeckhoven, C., APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129 (2006), 2977–2983.
37. Small, S.A., Gandy, S., Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52 (2006), 15–31.
38. Soares, H.D., Gasior, M., Toyn, J.H., Wang, J.S., Hong, Q., Berisha, F., Furlong, M.T., Raybon, J., Lentz, K.A., Sweeney, F., et al. The gamma secretase modulator, BMS-932481, modulates Abeta peptides in the plasma and CSF of healthy volunteers. J. Pharmacol. Exp. Ther. 358 (2016), 138–150.
39. Swinney, D.C., Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther. 93 (2013), 299–301.
40. Swinney, D.C., Anthony, J., How were new medicines discovered?. Nat. Rev. Drug Discov. 10 (2011), 507–519.
41. Szaruga, M., Veugelen, S., Benurwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., Ryan, N.S., Lashley, T., Fox, N.C., Murayama, S., et al. Qualitative changes in human gamma-secretase underlie familial Alzheimer's disease. J. Exp. Med. 212 (2015), 2003–2013.
42. Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
43. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
44. Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., Ihara, Y., gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29 (2009), 13042–13052.
45. Toyn, J.H., Boy, K.M., Raybon, J., Meredith, J.E., Roberston, A.S., Guss, V., Hoque, N., Sweeney, F., Zhuo, X., Clarke, W., et al. Robust translation of GSM pharmacology across preclinical species and human subjects. J. Pharmacol. Exp. Ther. 358 (2016), 125–137.
46. Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001), 212–216.
47. Wiseman, F.K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V.L., Fisher, E.M., Strydom, A., A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16 (2015), 564–574.
48. Wolstenholme, A.J., Rogers, A.T., Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 131:Suppl (2005), S85–S95.
49. Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., Suzuki, N., Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20 (2011), 4530–4539.
50. Yu, Y., Logovinsky, V., Schuck, E., Kaplow, J., Chang, M.K., Miyagawa, T., Wong, N., Ferry, J., Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel gamma-secretase modulator, E2212, in healthy human subjects. J. Clin. Pharmacol. 54 (2014), 528–536.